However, since primary human hepatocytes from adult liver lack the ability to proliferate in vitro, it is essential to establish a culture method for proliferation of human hepatic stem cells as a cell source and for differentiation of the cells to hepatocytes in vitro. 7) Recently, a transformation of the cultured stem cells, such as ES cells, has been reported 8) and a risk of tumorigenesis by using the cells should be discussed in the research field of regenerative medicine and bioartificial organs. Therefore, a proliferation of the stem cells in vitro without transformation is also a very important subject.
In our previous papers, 9, 10) we focused on the use of human fetal hepatocytes as a cell source for the bioartificial liver development. The cells could proliferate in monolayer along with lowering hepatic functions such as cytochrome P450 (CYP) activity and ammonia metabolizing activity, but the activities of the cells could be enhanced by the formation of spheroid on poly-L-glutamic acid coated dish. In general, fetal hepatocytes include hepatoblasts which are kinds of hepatic stem cells. 11, 12) Therefore, in this study, we examined the induction and proliferation of human hepatoblasts from fetal hepatocytes by the treatment of sodium butyrate (SB), which is well known as a differentiation-promoting agent of ES cells and so on, 13, 14) along with suppressing transformation. Furthermore, we investigated the functional expression of the cells at high cell density using porous hydroxyapatite carriers for the development of bioartificial liver.
MATERIALS AND METHODS

Cell and Culture Medium
Human fetal hepatocytes (Hc cells) were purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan) with a certification of informed consent for research. The delivered cells (1st passage, primary culture) were serially passaged with CS-C complete medium (Cell systems, Kirkland, WA, U.S.A.) that contained 10 ng/ml of acidic fibroblast growth factor and 10% fetal bovine serum as described in the previous paper, 9) and the 4th or the 5th passaged cells were used in all experiments. After inoculation of the cells to the culture dishes (35 mm of diameter) or the culture carriers with CS-C complete medium, the medium was exchanged at 4 h to CS-C complete medium containing SB (Sigma, MO, U.S.A.) and thereafter that was renewed at intervals of 2 d. SB was added to the medium at various concentrations in order to investigate the effect on induction of hepatoblasts from Hc cells. High Density Culture Porous hydroxyapatite carriers were donated from ABLE Corp. (Tokyo, Japan). The particle size was 600-1000 mm and the pore diameter was less than 100 mm. The average density was 1.96 cm 3 /g. 1.5ϫ10 5 cells were inoculated to 0.1 g of the carriers in the culture dish (35 mm diameter). The cells attached on the carriers were transferred to another dish and cultured for 14 d while keeping the glucose concentration of medium at more than 2.2 g/l by exchanging medium. The cell number was determined on the basis of glucose consumption rate.
Scanning Electron Microscopic (SEM) Observation
The cells attached on the carriers were fixed with 2% glutaraldehyde solution in 0.1 M cacodylate buffer. The fixed cells were gradually dehydrated in a series of ethanol solutions (70, 80, 90, 95%) and t-butanol solution (100%) for 2h, respectively. Dried samples were coated with gold using a sputter coater and observed by SEM (JSM-6301).
Analytical Methods The concentration of PIVKA-II, a clinical marker of hepatocellular carcinoma, 15) in the medium was measured by ELISA kit (Eisai, Tokyo, Japan). The PIVKA-II secretion rate of the cells was represented as the amount of PIVKA-II secreted during 1 d per 10 6 cells (mAU/ 10 6 cells/d). CYP3A4 activity of the cells was specifically induced by 10 mM rifampicin for 96 h and was measured as a benzyloxyresorufin-O-dealkylation (BROD) activity. The measurement medium contained 20 mM benzyloxyresorufin and 10 mM Dicumarol. Other conditions of measuring CYP activity were described in the previous paper.
10) Ammonia metabolizing activity was measured by using a commercial kit (Wako Pure Chemical Ind., Ltd., Osaka, Japan) as described in the previous paper.
9) Statistical analysis was carried out using Student's t-test. Value of pϽ0.05 was considered significant.
RESULTS AND DISCUSSION
Hepatoblasts are known to be hepatic stem cells in fetal liver, and differentiate into mature hepatocytes and biliary epithelial cells with the progress of fetal liver development. the population of hepatoblasts clearly increased by the treatment of 5 mM SB as shown in Figs. 1B and D. The ratio of hepatoblastic cell number to total cell number was investigated by flow cytometric analysis. As shown in Fig. 2 , about 80-90% of the cells were induced to be hepatoblasts by the treatment of 5 mM or 10 mM SB for 12 d of culture. The hepatoblast ratio depended on the SB concentration. The ratio was 90% under 5 mM SB and 30% under 1 mM SB for 12 d of culture. Figure 3 indicates the effect of SB on the growth of hepatoblasts. Although the growth was inhibited by 5 mM or 10 mM SB, the growth of hepatoblasts was maintained under 1 mM SB and hepatoblast density reached at 2.4ϫ10 5 cells in the dish (35 mm of diameter). Since the initial density of hepatoblasts was about 2.0ϫ10 3 cells in the dish which was analyzed by flow cytometry, the hepatoblasts proliferated about 120-fold for 12 d of culture. The doubling time (42 h) of human hepatoblast was much faster than that of other hepatic stem cells such as "small hepatocyte" from adult rat liver. 17) Furthermore, the transformation of hepatoblasts treated with SB was studied by using PIVKA-II assay, which is a clinical marker of hepatocellular carcinoma 15) and the PIVKA-II secretion rate of hepatocellular carcinoma (huH-2) was reported to be about 2100 mAU/10 6 cells/d. 18) As shown in Fig. 4 , the rate of Hc cells without treatment of SB was very low and the rate increased depending on the SB concentration. When more than 2.5 mM SB, the rate was slightly increased and it was suggested that the cells might be transformed by the treatment of high SB concentration. However, there was no significant difference in PIVKA-II secretion rate between the condition of 1 mM SB and control. Furthermore, the rates (0-12 mAU/10 6 cells/d) were sufficiently low as compared with that (2100 mAU/10 6 cells/d) of hepatocellular carcinoma. These results indicated that hepatoblasts could be induced and proliferate under 1 mM SB with suppressing transformation. It is well known that SB is a histone deacetylase (HDAC) inhibitor 13) and involved in the differen- tiation of ES cells to hepatocytes.
14) The induction, proliferation and transformation of hepatoblasts are thought to be linked with HDAC activity and gene expression related to deacetylation of histone.
High density culture and functional expression of the cells were also investigated using porous hydroxyapatite carriers (Fig. 5A) for their applications to bioartificial liver. It is well known that porous carriers are effective for high density culture of adherent cells and hydroxyapatite carrier or scaffold are biocompatible material for artificial organs. 19) Hc cells could proliferate in the hydroxyapatite carriers and the cell density attained to 3.0ϫ10 7 cells/cm 3 in the carriers ( Table  1) . The cells treated with 1 mM SB also kept proliferative ability and attained to about 1.0ϫ10 7 cells/cm 3 in the carriers (Fig. 5B) . CYP3A4 is known to be a major isozyme of human CYP family. 20) The CYP3A4 activity of the cells was significantly enhanced by the treatment of 1 mM SB in the carriers compared to the cells with no treatment (control) as shown in Table 1 . 4.2 pmol/mg protein/min of CYP3A4 activity was comparable to that (2.9 pmol/mg protein/min) of primary human hepatocytes from adult liver of donor. 20) Ammonia metabolizing activity (0.21 mmol/10 6 cells/h) of the cells in the carriers, which is an important activity of bioartificial liver for therapy of hepatic coma, 21) was obtained by the treatment of 1 mM SB and comparable to that (0.17 mmol/ 10 6 cells/h) of porcine hepatocytes used in the bioartificial liver. 22, 23) The PIVKA-II secretion rate of the cells in the carriers was also suppressed to about 12 mAU/10 6 cells/d by the treatment of 1 mM SB (Table 1) , which was almost comparable to that of monolayer culture on the dish as shown in Fig. 4 .
From these results, it was suggested that the cells treated with 1 mM SB and cultured in the hydroxyapatite carriers could express some differentiated functions at a comparable level with primary hepatocytes. It might be possible to get a functional human hepatocytes of about 10 10 cells by designing a bioreactor of 1000 cm 3 -volume at 1.0ϫ10 7 cells/cm 3 of cell density. This volume should be fully achievable as a clinically applicable scale of bioartificial liver. Although the use of human fetal hepatocytes for bioartificial liver seems to involve a bioethical issue, the isolation of human hepatoblasts from fetal hepatocytes treated with SB and the establishment of cell line from the cells without transformation in the future is worth considering.
In the present study, we have established a promising culture method for proliferation of human hepatic stem cells and for the functional expression of the cells in vitro for the bioartificial liver development. 
